Biontech completes acquisition of kite's neoantigen tcr cell therapy r&d platform and manufacturing facility in gaithersburg, maryland

Mainz, germany & santa monica, usa, august 4, 2021 –  biontech se  (nasdaq: bntx, “biontech”) and kite , a gilead company (nasdaq: gild, “kite”) today announced the closing of the acquisition of the solid tumor neoantigen t cell receptor (tcr) r&d platform and clinical manufacturing facility's assets and leases in gaithersburg, md, from kite. the transaction was announced on july 19, 2021.
BNTX Ratings Summary
BNTX Quant Ranking